Although therapies aiming to boost the immune system (immunotherapies) have rapidly become one of the most successful cancer treatments, most patients fail to benefit from those therapies, underlining the lack of understanding of mechanisms regulating our immune system. In this regard, my current research focuses on determining how epigenetic factors govern the functionality of our immune system. Ultimately, I hope my research could pave the way toward new druggable epigenetic targets that can improve immunotherapies and, consecutively, patient quality of life.
Following my MSc in Medical Biology, I obtained a Ph.D. in the Urology Department at the Lausanne University Hospital (CHUV, Switzerland). The CHUV is a world-renowned research hub that works closely with academic institutions, enabling scientists and clinicians to cooperate in developing cancer treatments. In this regard, my thesis was based on a translational approach and consisted of 1) characterising neoantigen-reactive CD8+ T cells and 2) determining the role of gamma delta T cells in the pathophysiology of patients with bladder cancer.
Phenotype and Reactivity of Lymphocytes Expanded from Benign Prostate Hyperplasic Tissues and Prostate Cancer.
Ahmed R. et al, (2023), Cancers, 15
Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety Profile.
Lucca I. et al, (2022), European urology open science, 45, 55 - 58
Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments.
Nguyen S. et al, (2022), Journal for immunotherapy of cancer, 10
Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
Benmerzoug S. et al, (2022), European urology focus, 8, 748 - 751
Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer Patients.
Benmerzoug S. et al, (2021), European urology open science, 34, 79 - 82